

|  |
| --- |
| Prophylactic use of RhD immunoglobulin for RhD-negative women |
| **Accessible text-equivalent version** |

* Maternal RhD antibodies may develop during pregnancy when an RhD negative pregnant woman carries an Rh D positive fetus.
* Perform ABO and RhD blood groups and antibody screen early in pregnancy.
* Test maternal blood to determine fetal RhD genotype from 11 weeks (note current restricted use).See [Testing of maternal blood group to determine fetal RhD genotype](https://www.blood.gov.au/testing-maternal-blood-determine-fetal-rhd-genotype) <https://www.blood.gov.au/testing-maternal-blood-determine-fetal-rhd-genotype>.
* Give RhD immunoprophylaxis (625 IU) at 28 and 34 weeks for RhD negative women with known RhD positive fetus, or where the RhD group of the fetus is unknown.

# Sensitising events require RhD immunoglobin (RhD Ig)

[Prophylactic use of RhD immunoglobulin in pregnancy care 2021](https://www.blood.gov.au/sites/default/files/Guideline%20for%20the%20prophylactic%20use%20of%20Rh%20D%20immunoglobulin%20in%20pregnancy%20care.pdf) <https://www.blood.gov.au/sites/default/files/Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care.pdf> – refer to pages 4–5.

| Within the first 12 weeks | Between 13–20 weeks | After 20 weeks | Post-partum if RhD-positive baby |
| --- | --- | --- | --- |
| Give 250 IU RhD Ig as soon as practical within 72 hours of event. | Give 625 IU RhD Ig as soon as practical within 72 hours of event. | Give 625 IU RhD Ig as soon as practical within 72 hours of event. Additional doses may be required based on fetomaternal haemorrhage (FMH) quantification. | Give 625 IU RhD Ig as soon as practical. Additional doses may be required based on FMH quantification. |

|  |
| --- |
| For more information:   * [Guideline for the prophylactic use of RhD immunoglobulin in pregnancy care](https://www.blood.gov.au/sites/default/files/Guideline%20for%20the%20prophylactic%20use%20of%20Rh%20D%20immunoglobulin%20in%20pregnancy%20care.pdf) [PDF] <https://www.blood.gov.au/sites/default/files/Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care.pdf> * [Prophylactic use of RhD immunoglobulin in pregnancy care](https://www.blood.gov.au/anti-d-0) <https://www.blood.gov.au/anti-d-0> * [Guidelines for transfusion and immunohaematology laboratory practice [PDF]](https://anzsbt.org.au/wp-content/uploads/2021/04/Guideline_-for_Transfusion_and_Immunohaematology_Laboratory_Practice_FINAL_Published_20210426.pdf) <https://anzsbt.org.au/wp-content/uploads/2021/04/Guideline\_-for\_Transfusion\_and\_Immunohaematology\_Laboratory\_Practice\_FINAL\_Published\_20210426.pdf> |

|  |
| --- |
| To receive this document in another format, phone 03 9694 0102 using the National Relay Service 13 36 77 if required, or email [Blood Matters](mailto:Blood%20Matters) <bloodmatters@redcrossblood.org.au>.  Authorised and published by the Victorian Government, 1 Treasury Place, Melbourne.  © State of Victoria, Australia, Department of Health, May 2022.  **ISBN** 978-1-76096-751-2 **(pdf/online/MS word)**  Available at [Blood Matters](https://www.health.vic.gov.au/patient-care/blood-matters-program) <https://www.health.vic.gov.au/patient-care/blood-matters-program> |